Russell Investments Group
INDP icon

Russell Investments Group’s Indaptus Therapeutics INDP Stock Holding History

Russell Investments Group’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-47
Closed -$29K – 3221
2020
Q2 		$29K Buy
+47
New +$29K ﹤0.01% 3030

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Russell Investments Group's INDP Position: Q3 2020 in Review

Russell Investments Group sold out of Indaptus Therapeutics (INDP) in Q3 2020, closing a stake of 47 shares — an estimated $29K sold.

Russell Investments Group first reported a position in INDP in Q2 2020 and held it in 1 quarter. The position peaked at $29K in Q2 2020. 24 funds tracked by Wall St. Rank hold INDP as of Q3 2020.

  • Russell Investments Group reported no remaining Indaptus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Russell Investments Group sold 47 Indaptus Therapeutics shares in Q3 2020, an estimated $29K.
  • Russell Investments Group first reported a position in Indaptus Therapeutics in Q2 2020 and held it in 1 quarter.
  • Russell Investments Group's Indaptus Therapeutics position peaked at $29K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2020.

Based on Russell Investments Group's 13F filing for Q3 2020, filed 9 Nov 2020.